Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality9/10

Nasus Pharma appoints new CEO as NS002 advances toward pivotal 2026 milestones

Aug 17, 2026, 8:17 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

CEO appointment and near-term NS002 milestones create upside potential; mix of cash runway, topline data, and pivotal-trial timing has historically driven re-ratings in clinical-stage names with meaningful inflection points.

AI summary

What happened, with direct paths to the underlying reporting

Nasus Pharma appointed Brendan O’Grady as CEO and announced progress in NS002 and NS003. NS002 Phase 2 topline data show faster time to therapeutic threshold versus EpiPen, with a pivotal trial slated for Q4 2026 and topline data in Q1 2027. The company also plans a first-in-human PK study for NS003 in the coming weeks, while maintaining a cash runway through 2Q2027 after a $15 million raise.

Nasus appoints Brendan O’Grady as CEO; targets H2 2026 milestones.
NS002 Phase 2 shows faster T100 vs EpiPen; pivotal study planned Q4 2026.
NS003 PK first-in-human planned in coming weeks.
Cash at 6/30/2026: $11.9M; $15M gross private placement; runway to 2Q2027.
Six months ended 6/30/2026: net loss $5.9M; R&D $2.6M; G&A $3.4M.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Nasus Pharma appoints new CEO as NS002 advances toward pivotal 2026 milestones

Nasus Pharma's NS002 Shows Promise Despite Recent Stock Decline